← back to search

Kara W Chew

University of California, Los Angeles · US
Area of research
Infectious Diseases · Hepatology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Hepatitis C virus research, and Long-Term Effects of COVID-19.
h-index
22
citations
1,662
works
150
NIH funding
primary concept
Medicine
email

Recent publications

Association of long COVID with health-related quality-of-life outcomes
Scientific Reports 2026cited by 0position: middledoi
Correlates of HIV-1 control after combination immunotherapy
Nature 2025cited by 21position: middledoi
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
Clinical Infectious Diseases 2025cited by 13position: middledoi
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV
JAMA Cardiology 2024cited by 77position: middledoi
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned
Annals of Internal Medicine 2024cited by 43position: middledoi
Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial
Clinical Infectious Diseases 2024cited by 14position: middledoi
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis
Clinical Infectious Diseases 2024cited by 13position: middledoi
SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback
The Journal of Infectious Diseases 2024cited by 13position: middledoi
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
Annals of Internal Medicine 2023cited by 63position: middledoi
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial
Nature Microbiology 2022cited by 53position: middledoi
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
Nature Communications 2022cited by 48position: firstdoi
Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques
Frontiers in Immunology 2022cited by 28position: middledoi
Liver Inflammation Is Common and Linked to Metabolic Derangements in Persons With Treated Human Immunodeficiency Virus (HIV)
Clinical Infectious Diseases 2022cited by 11position: firstdoi
Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus
Clinical Gastroenterology and Hepatology 2020cited by 63position: middledoi
Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016
PLoS ONE 2018cited by 59position: middledoi
Hepatitis E Virus–Associated Meningoencephalitis in a Lung Transplant Recipient Diagnosed by Clinical Metagenomic Sequencing
Open Forum Infectious Diseases 2017cited by 78position: middledoi
Demographics and natural history of HIV-1-infected spontaneous controllers of viremia
AIDS 2017cited by 58position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Jonathan Z. Li · Harvard University3 papers (2022–2025)Eric S. Daar · UCLA Medical Center3 papers (2022–2025)Courtney V. Fletcher · University of North Carolina at Chapel Hill2 papers (2022–2025)Joseph J. Eron · University of North Carolina at Chapel Hill2 papers (2022–2025)Davey M. Smith · Imperial College London2 papers (2022–2025)Susanna Naggie · Duke University2 papers (2020–2022)Mark Sulkowski · Johns Hopkins Bayview Medical Center2 papers (2020–2022)David A. Wohl · University of North Carolina at Chapel Hill2 papers (2022–2025)Judith S. Currier · MGH Institute of Health Professions2 papers (2022–2025)Frank J. Palella · University of Rochester Medical Center2 papers (2018–2022)Michael D. Hughes · Virginia Tech2 papers (2022–2025)Rinki Deo · Harvard University1 papers (2022–2022) · 1 papers (2017–2017)Cristina Bergamaschi · Center for Cancer Research1 papers (2022–2022)Edgar T. Overton · AIDS Clinical Trials Group1 papers (2022–2022)Steven C. Johnson · University of Colorado Denver1 papers (2024–2024) · 1 papers (2024–2024)Deanna Ware · Georgetown University1 papers (2018–2018) · 1 papers (2024–2024) · 1 papers (2022–2022)